Ito Kyoji, Ohmagari Norio, Mikami Ayako, Sugiura Wataru
National Center for Global Health and Medicine, Tokyo, Japan.
Glob Health Med. 2020 Apr 30;2(2):96-101. doi: 10.35772/ghm.2020.01034.
The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to global public health and economies. Currently, hundreds of clinical trials on a wide variety of treatments against COVID-19 are being conducted around the world. Here, we conducted a search for ongoing clinical trials for the treatment of COVID-19 at the clinicaltrials.gov database on April 2, 2020. In total, 48 clinical trials were identified, and of these, 41 trials adopted drug intervention and the other 7 trials utilized biological intervention. The number of trials stratified by a chief country conducting the investigation were 18 in China, 5 in the United States, 4 in Canada, 3 in Italy, 2 in France and Brazil, and 4 trials are being performed multinationally. The drugs utilized in more than one trials were remdesivir (6 trials), lopinavir/ritonavir (6 trials), hydroxychloroquine (6 trials), interferon (5 trials), methylprednisolone (3 trials), nitric oxide gas (3 trials), oseltamivir (2 trials), arbidol (2 trials), and vitamin C (2 trials). We also described the Japanese trials which are now being conducted or scheduled, utilizing lopinavir/ritonavir, remdesivir, favipiravir, ciclesonide and nafamostat.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 冠状病毒病（COVID-19）疫情对全球公共卫生和经济构成了严重威胁。目前，全球正在进行数百项针对 COVID-19 的各种治疗方法的临床试验。在此，我们于 2020 年 4 月 2 日在 clinicaltrials.gov 数据库中搜索了正在进行的 COVID-19 治疗临床试验。总共确定了 48 项临床试验，其中 41 项试验采用药物干预，另外 7 项试验采用生物干预。按主要开展调查的国家分层的试验数量分别为：中国 18 项、美国 5 项、加拿大 4 项、意大利 3 项、法国和巴西各 2 项，还有 4 项试验正在多国进行。在不止一项试验中使用的药物有瑞德西韦（6 项试验）、洛匹那韦/利托那韦（6 项试验）、羟氯喹（6 项试验）、干扰素（5 项试验）、甲泼尼龙（3 项试验）、一氧化氮气体（3 项试验）、奥司他韦（2 项试验）、阿比多尔（2 项试验）和维生素 C（2 项试验）。我们还描述了目前正在进行或计划进行的日本试验，这些试验使用了洛匹那韦/利托那韦、瑞德西韦、法匹拉韦、环索奈德和那法莫司他。
